Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
作者： G Falkson , J M MacIntyre , A J Schutt , B Coetzer , L A Johnson
关键词:
摘要: Sixty-one of 76 patients entered on a prospective randomized trial neocarzinostatin ( NCZ ) versus m-AMSA or doxorubicin were eligible for analysis. Among these 61 at least one episode severe toxicity was documented in 39% and 58% m-AMSA. Fifty-one the previously untreated with chemotherapy. 51 objective response two 25 treated , none 17 m-AMSA, nine doxorubicin. North American European (NA/E) median survival times were: 11 weeks 12 weeks. The data South African (SA) similar entrance criteria earlier Eastern Cooperative Oncology Group trials analyzed that from show SA (31 patients); 13 (33 doxorubicin, 15 (29 patients).
sci-hub.se 参考文章(7)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Geoffrey Falkson, Buks Coetzer, DavidJ. Klaassen, A phase II study of m-AMSA in patients with primary liver cancer Cancer Chemotherapy and Pharmacology. ,vol. 6, pp. 127- 129 ,(1981) , 10.1007/BF00262329
G. Falkson, D. Von Hoff, D. Klaassen, Helene Du Plessis, C. F. Van Der Merwe, Alma M. Van Der Merwe, P. P. Carbone, A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study. Cancer Chemotherapy and Pharmacology. ,vol. 4, pp. 33- 36 ,(1980) , 10.1007/BF00255455
Edgar Cheng, Charles Lightdale, Charles Young, Alan Yagoda, Joseph Fortner, Robert Golbey, Phase II trial of (m-AMSA) 4'-9-(acridinylamino)-methanesulfon-m-aniside in primary liver cancer. American Journal of Clinical Oncology. ,vol. 6, pp. 211- 214 ,(1983) , 10.1097/00000421-198304000-00013
G. H. FREEMAN, J. H. HALTON, NOTE ON AN EXACT TREATMENT OF CONTINGENCY, GOODNESS OF FIT AND OTHER PROBLEMS OF SIGNIFICANCE Biometrika. ,vol. 38, pp. 141- 149 ,(1951) , 10.1093/BIOMET/38.1-2.141
Martin M. Oken, Richard H. Creech, Douglass C. Tormey, John Horton, Thomas E. Davis, Eleanor T. McFadden, Paul P. Carbone, Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology. ,vol. 5, pp. 649- 655 ,(1982) , 10.1097/00000421-198212000-00014